Antimicrobial Agents and Chemotherapy · 2009 · 80 citations · 11 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacologyAntimicrobial ResistanceMedical MicrobiologyAntibiotic ResistanceBacterial InfectionsResistance In Gram-negative BacteriaResistance In Gram-positive BacteriaEscherichia ColiFluoroquinolone AntibioticsResistance In Clinical IsolatesResistance Mechanisms In Staphylococci
The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC(90)/range [microg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/< or = 0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC(90)/range [microg/ml]; Escherichia coli, 32/< or = 0.015 to > or = 512; Klebsiella pneumoniae, 2/< or = 0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to > or = 512; Pseudomonas aeruginosa, 32/< or = 0.015 to > or = 512; Acinetobacter baumannii, 1/0.12 to 16).
11
M. R. Mulvey, Linda Chui, Johanne Ismaïl et al. · Journal of Clinical Microbiology · 2001 · 253 citations
George G. Zhanel, Melanie DeCorby, Heather J. Adam et al. · Antimicrobial Agents and Chemotherapy · 2010 · 170 citations · Full text
George R. Golding, Jennifer Campbell, Dave Spreitzer et al. · Canadian Journal of Infectious Diseases and Medical Microbiology · 2008 · 67 citations · Full text
Kimberly A. Nichol, Heather J. Adam, Zafar Hussain et al. · Diagnostic Microbiology and Infectious Disease · 2011 · 65 citations